Ind-Swift Laboratories Ltd (INDSWFTLAB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 393806, "name": "Ind-Swift Labs.", "stock_name": "Ind-Swift Labs.", "full_name": "Ind-Swift Laboratories Ltd", "name_url": "stocks-analysis/ind-swift-labs", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "162.80", "chg": 1.2, "chgp": "0.74%", "dir": 1, "prev_price": "161.60", "mcapval": "1,452.00 Cr", "mcap": "Micro Cap", "scripcode": 532305, "symbol": "INDSWFTLAB", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE915B01019", "curr_date": "Jun 10, 03:30 PM", "curr_time": "04:53 AM", "last_traded_at": "Jun 10, 03:30 PM IST", "bse_nse_vol": "14.19 lacs", "exc_status": "Active", "traded_date": "Jun 10, 2026", "traded_date_str": "2026 06 10", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ind-swift-labs-393806-0&utm_source=Spage_Header_Score", "mojoone": { "text": "Part of MojoOne Strategy", "type": "MN", "url": "https://www.marketsmojo.com/mojopro/strategy/2", "ismore": 0, "all_data": [], "is_blur": 1, "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ind-swift-labs-393806-0&utm_source=Spage_Score_PartofStrategies" } }, "news": { "results": [ { "title": "Ind-Swift Laboratories Ltd Upgraded to Hold on Technical and Financial Improvements", "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-ltd-upgraded-to-hold-on-technical-and-financial-improvements-4030134", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IndSwiftLaborat_mojoScore_4030134.png", "date": "2026-06-02 08:42:29", "description": "Ind-Swift Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and recent financial results. The upgrade, effective from 1 June 2026, is driven by enhanced technical trends, robust quarterly sales growth, and a strong market performance relative to benchmarks, despite lingering concerns over long-term fundamentals and profitability." }, { "title": "Ind-Swift Laboratories Ltd Sees Bullish Momentum Shift Amid Strong Technical Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-ltd-sees-bullish-momentum-shift-amid-strong-technical-signals-4029307", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IndSwiftLaborat_technicaldot_4029307.png", "date": "2026-06-02 08:03:09", "description": "Ind-Swift Laboratories Ltd has witnessed a significant shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by strong weekly and monthly MACD signals, bullish moving averages, and a notable 8.00% gain in a single trading session, signalling renewed investor interest in this micro-cap pharmaceutical player." }, { "title": "Broad-Based Technical Strength Lifts Ind-Swift Laboratories Ltd to 52-Week High of Rs 166.85", "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-ltd-hits-new-52-week-high-at-rs16685-4025777", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IndSwiftLaborat_priceRelatedfactors_4025777.png", "date": "2026-06-01 09:45:51", "description": "With a surge to Rs 166.85 on 1 Jun 2026, Ind-Swift Laboratories Ltd has reached a fresh 52-week high, marking a remarkable 95.55% gain over the past year. This milestone is underpinned by a confluence of technical indicators signalling sustained momentum, even as the broader Sensex trades near its own lows." }, { "title": "Ind-Swift Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-ltd-is-rated-sell-4024231", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IndSwiftLaborat_mojoScore_4024231.png", "date": "2026-05-31 10:10:42", "description": "Ind-Swift Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Are Ind-Swift Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-ind-swift-laboratories-ltd-latest-results-good-or-bad-4023811", "imagepath": "", "date": "2026-05-30 19:44:57", "description": "Ind-Swift Laboratories Ltd's latest financial results for the quarter ended March 2026 reflect notable operational trends. The company reported net sales of ₹169.79 crores, marking a year-on-year growth of 22.82%, which indicates a recovery in demand for its API products. This growth is significant as it contrasts sharply with the previous year's decline of 73.85%. The sequential increase of 12.56% from the previous quarter also suggests a positive momentum in sales.\n\nNet profit for the same quarter stood at ₹15.11 crores, which, while showing a quarter-on-quarter improvement of 58.39%, reflects a substantial year-on-year decline of 93.20%. This decline is largely attributed to the extraordinary items that inflated profits in the prior year, making direct comparisons less meaningful.\n\nThe operational margins exhibited improvement, with the operating margin reaching 12.12%, the highest in the last seven quar..." }, { "title": "Ind-Swift Laboratories Surges 15.16%: Key Drivers Behind the Rally", "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-surges-1516-key-drivers-behind-the-rally-4023591", "imagepath": "", "date": "2026-05-30 17:16:04", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 25:</strong> Modest gain of 0.08% amid broad market rally</p>\n <p><strong>May 26:</strong> Sharp 2.99% rise despite Sensex decline</p>\n <p><strong>May 27:</strong> Minor pullback of 0.85% on low volume</p>\n <p><strong>May 29:</strong> New 52-week high at Rs.158.15 and strong Q4 FY26 results</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.131.95</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.151.95</div><div class=\"stat-c..." }, { "title": "Ind-Swift Laboratories Q4 FY26: Turnaround Gains Momentum as Profitability Returns", "link": "https://www.marketsmojo.com/news/result-analysis/ind-swift-laboratories-q4-fy26-turnaround-gains-momentum-as-profitability-returns-4022125", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IndSwiftLaborat_quaterlyResult_4022125.png", "date": "2026-05-29 16:23:25", "description": "Ind-Swift Laboratories Ltd., a Chandigarh-based active pharmaceutical ingredients (API) manufacturer, reported a consolidated net profit of ₹15.11 crores for Q4 FY26 (Mar'26), marking a significant 58.39% quarter-on-quarter improvement from ₹9.54 crores in Q3 FY26 (Dec'25). However, on a year-on-year basis, the profit declined sharply by 93.20% from an exceptional ₹222.27 crores in Q4 FY25, which was inflated by extraordinary gains. The company's stock surged 12.68% to ₹151.95 following the results announcement, reflecting investor optimism about the operational turnaround." }, { "title": "Broad-Based Technical Strength Lifts Ind-Swift Laboratories Ltd to 52-Week High of Rs 158.15", "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-ltd-hits-new-52-week-high-at-rs15815-4019593", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IndSwiftLaborat_priceRelatedfactors_4019593.png", "date": "2026-05-29 09:42:48", "description": "Surging past its previous peaks, Ind-Swift Laboratories Ltd touched a fresh 52-week high of Rs 158.15 on 29 May 2026, marking a remarkable rally that has more than doubled its share price from the low of Rs 77.09 recorded last year. This milestone underscores the stock’s strong price momentum amid a mixed broader market backdrop." }, { "title": "Ind-Swift Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-ltd-is-rated-sell-4000720", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IndSwiftLaborat_mojoScore_4000720.png", "date": "2026-05-20 10:10:56", "description": "Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with the latest insights into the company's performance and outlook." } ], "total": 199, "sid": "393806", "stock_news_url": "https://www.marketsmojo.com/news/ind-swift-laboratories-393806" }, "announcements": [ { "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance", "datetime": "30-May-2026", "details": "Please refer attached pdf.", "source": "BSE" }, { "caption": "Board Meeting Outcome for Audited Financial Results For The Quarter And Financial Year Ended 31St March 2026", "datetime": "28-May-2026", "details": "Audited Financial results for the Quarter and Financial year ended 31st March 2026", "source": "BSE" }, { "caption": "Statement Of NIL Deviation For The Quarter Ended March 31 2026", "datetime": "28-May-2026", "details": "Please refer attached pdf.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Ind-Swift Laboratories Ltd has declared <strong>10%</strong> dividend, ex-date: 20 Sep 11", "dt": "2011-09-20", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

May 25: Modest gain of 0.08% amid broad market rally

May 26: Sharp 2.99% rise despite Sensex decline

May 27: Minor pullback of 0.85% on low volume

May 29: New 52-week high at Rs.158.15 and strong Q4 FY26 results

Read full news article

Ind-Swift Laboratories Q4 FY26: Turnaround Gains Momentum as Profitability Returns

2026-05-29 16:23:25

Ind-Swift Laboratories Ltd., a Chandigarh-based active pharmaceutical ingredients (API) manufacturer, reported a consolidated net profit of ₹15.11 crores for Q4 FY26 (Mar'26), marking a significant 58.39% quarter-on-quarter improvement from ₹9.54 crores in Q3 FY26 (Dec'25). However, on a year-on-year basis, the profit declined sharply by 93.20% from an exceptional ₹222.27 crores in Q4 FY25, which was inflated by extraordinary gains. The company's stock surged 12.68% to ₹151.95 following the results announcement, reflecting investor optimism about the operational turnaround.

Read full news article

Broad-Based Technical Strength Lifts Ind-Swift Laboratories Ltd to 52-Week High of Rs 158.15

2026-05-29 09:42:48

Surging past its previous peaks, Ind-Swift Laboratories Ltd touched a fresh 52-week high of Rs 158.15 on 29 May 2026, marking a remarkable rally that has more than doubled its share price from the low of Rs 77.09 recorded last year. This milestone underscores the stock’s strong price momentum amid a mixed broader market backdrop.

Read full news article

Ind-Swift Laboratories Ltd is Rated Sell

2026-05-20 10:10:56

Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with the latest insights into the company's performance and outlook.

Read full news article